References
- 1World Health Organisation.
Global action plan for the prevention and control of non-communicable diseases . Geneva: World Health Organization; 2013. - 2Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet. 2016; 387(10013): 61–9. DOI: 10.1016/S0140-6736(15)00469-9
- 3Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011; 378(9798): 1231–43. DOI: 10.1016/S0140-6736(11)61215-4
- 4Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, Patel AA. Gaps in cardiovascular disease risk management in Australian general practice. Medical Journal Of Australia. 2009; 191(6): 324–9. DOI: 10.5694/j.1326-5377.2009.tb02816.x
- 5Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012. Journal of the American Heart Association. 2015; 4(4). DOI: 10.1161/JAHA.114.001709
- 6Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in vascular risk factor treatment and control in US stroke survivors: the National Health and Nutrition Examination Surveys (1999–2010). Circulation Cardiovascular quality and outcomes. 2013; 6(3): 270–7. DOI: 10.1161/CIRCOUTCOMES.113.000112
- 7World Health Organisation.
Treatment of Tuberculosis Guidelines . Geneva: World Health Organization; 2010. - 8World Health Organization.
Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key population – 2016 update . Geneva: World Health Organization; 2016. - 9Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368(9534): 505–10. DOI: 10.1016/S0140-6736(06)69158-7
- 10Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient preference and adherence. 2011; 5: 357–67. DOI: 10.2147/PPA.S22771
- 11Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient preference and adherence. 2010; 4: 115–25. DOI: 10.2147/PPA.S10330
- 12World Health Organization.
Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions . Geneva. 2002. - 13Munoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med. 2019; 381(12): 1114–23. DOI: 10.1056/NEJMoa1815359
- 14Indian Polycap S, Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet. 2009; 373(9672): 1341–51. DOI: 10.1016/S0140-6736(09)60611-5
- 15Pill Collaborative Group, Rodgers A, Patel A, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011; 6(5):
e19857 . DOI: 10.1371/journal.pone.0019857 - 16Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. International journal of clinical practice. 2010; 64(9): 1220–7. DOI: 10.1111/j.1742-1241.2010.02412.x
- 17Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE. 2012; 7(7):
e41297 . DOI: 10.1371/journal.pone.0041297 - 18Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): A pragmatic, cluster-randomised trial. Lancet. 2019; 394(10199): 672–83. DOI: 10.1016/S0140-6736(19)31791-X
- 19Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: Results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. Journal of the American College of Cardiology. 2014.
- 20Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European journal of preventive cardiology. 2014. DOI: 10.1177/2047487314530382
- 21Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014; 348. DOI: 10.1136/bmj.g3318
- 22Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA: the journal of the American Medical Association. 2013; 310(9): 918–29. DOI: 10.1001/jama.2013.277064
- 23Webster R, Patel A, Selak V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. International journal of cardiology. 2016; 205: 147–56. DOI: 10.1016/j.ijcard.2015.12.015
- 24Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: Effective in improving adherence but are they safe? Ther Adv Drug Saf. 2018; 9(2): 157–62. DOI: 10.1177/2042098617747836
- 25Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension. 2010; 55(2): 399–407. DOI: 10.1161/HYPERTENSIONAHA.109.139816
- 26Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018; 15(6): e1002584. DOI: 10.1371/journal.pmed.1002584
- 27Webster R, Salam A, de Silva HA, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs. Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA: The journal of the American Medical Association. 2018; 320(6): 566–79. DOI: 10.1001/jama.2018.10359
- 28Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017. DOI: 10.22141/2307-1257.7.1.2018.122220
- 29Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021–104. DOI: 10.1093/eurheartj/ehy339
- 30Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: Health effects and costs. The Lancet. 2007; 370(9604): 2054–62. DOI: 10.1016/S0140-6736(07)61699-7
- 31World Health Organization.
‘Best buys’ and other recommended interventions for the prevention and control of non-communicable diseases . Tackling NCDs. Geneva; 2017. - 32World Health Organization.
HEARTS: Technical package for cardiovascular disease management in primary health care . Geneva: World Health Organization; 2016. - 33Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet. 2017; 389(10073): 1066–74. DOI: 10.1016/S0140-6736(17)30558-5